We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session

News   Nov 18, 2010

 
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
 
 
Advertisement
 

RELATED ARTICLES

Expert Panel Makes Weak Recommendation for Use of Remdesivir To Treat Severe COVID-19

News

International experts have made a weak recommendation for the use of remdesivir in patients with severe COVID-19, advising continuation of patient enrolment for ongoing clinical trials of remdesivir to enable the collection of additional data.

READ MORE

Positive Results Reported for Phase 2 Study of Lyme Disease Vaccine Candidate

News

Positive initial results have been reported for the Phase 2 study of Lyme disease vaccine candidate VLA15.

READ MORE

Pan-Bcl-2 and Bcl-xL-Specific Inhibitors: Adverse Effects From Cancer Drug Trials Explained

News

A certain type of cancer drug, known as pan-Bcl-2 or Bcl-xL-specific inhibitors, that promote the apotosis can actually be harmful if combined with other treatments that damage our DNA, RNA or proteins, researchers have found.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE